Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

687.70INR
5:17am EST
Change (% chg)

Rs15.10 (+2.25%)
Prev Close
Rs672.60
Open
Rs678.75
Day's High
Rs690.45
Day's Low
Rs674.85
Volume
634,515
Avg. Vol
777,513
52-wk High
Rs746.50
52-wk Low
Rs335.00

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.53
Market Cap(Mil.): Rs293,218.31
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 38.99 40.21
EPS (TTM): -19.13 -- --
ROI: -- 17.01 16.34
ROE: -- 17.53 17.27
Search Stocks

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

30 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

30 Jan 2015

UPDATE 1-Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

30 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sells its interest in a generic anti-bacterial medicine, the Federal Trade Commission said on Friday.

30 Jan 2015

India's Ranbaxy Dec qtr net loss widens on forex loss

MUMBAI, Jan 28 - Indian generic drugmaker Ranbaxy Laboratories Ltd reported a wider loss in the December quarter, hurt by foreign exchange losses and higher finance costs.

28 Jan 2015

India's regulator clears Sun Pharma-Ranbaxy deal

MUMBAI - India's antitrust regulator approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

India's regulator clears Sun Pharma-Ranbaxy deal

MUMBAI - India's antitrust regulator approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

08 Dec 2014

UPDATE 1-India's regulator clears Sun Pharma-Ranbaxy deal

(Adds details from CCI order, comments from Sun and Ranbaxy, background)

08 Dec 2014

India's antitrust regulator clears Sun Pharma-Ranbaxy deal

MUMBAI, Dec 8 - India's antitrust regulator said on Monday it has approved generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.

08 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

08 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: Motilal Oswal Securities Ltd.
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks